{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:58:22Z","timestamp":1787795902639,"version":"build-2784847793"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.msard.2022.103995","type":"journal-article","created":{"date-parts":[[2022,6,26]],"date-time":"2022-06-26T12:47:37Z","timestamp":1656247657000},"page":"103995","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"special_numbering":"C","title":["Use of natalizumab in persons with multiple sclerosis: 2022 update"],"prefix":"10.1016","volume":"65","author":[{"given":"Sarah A.","family":"Morrow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fraser","family":"Clift","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Devonshire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Lapointe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Stefanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Vosoughi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2022.103995_bib0001","series-title":"TYSABRI (natalizumab) product monograph","year":"2017"},{"issue":"8","key":"10.1016\/j.msard.2022.103995_bib0002","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1212\/WNL.0000000000002395","article-title":"Comparative efficacy of fingolimod vs natalizumab: a French multicenter observational study","volume":"86","author":"Barbin","year":"2016","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.msard.2022.103995_bib0003","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1177\/1352458516650736","article-title":"Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies","volume":"22","author":"Baroncini","year":"2016","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.msard.2022.103995_bib0004","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1177\/1352458520936239","article-title":"Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort","volume":"27","author":"Bigaut","year":"2021","journal-title":"Mult. Scler."},{"issue":"20","key":"10.1016\/j.msard.2022.103995_bib0005","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2022.103995_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.699844","article-title":"Long-term efficacy outcomes of natalizumab vs. fingolimod in patients with highly active relapsing-remitting multiple sclerosis: real-world data from a multiple sclerosis reference center","volume":"12","author":"Boziki","year":"2021","journal-title":"Front. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2022.103995_bib0007","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1007\/s00415-013-7082-0","article-title":"Second line use of fingolimod is as effective as natalizumab in a German out-patient RRMS-cohort","volume":"260","author":"Braune","year":"2013","journal-title":"J. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2022.103995_bib0008","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/jnnp-2013-306936","article-title":"Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results","volume":"85","author":"Butzkueven","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2022.103995_bib0009","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211042458","article-title":"No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)","volume":"14","author":"Butzkueven","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"6","key":"10.1016\/j.msard.2022.103995_bib0010","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/jnnp-2019-322326","article-title":"Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)","volume":"91","author":"Butzkueven","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"10","key":"10.1016\/j.msard.2022.103995_bib0011","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-038861","article-title":"Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study","volume":"10","author":"Butzkueven","year":"2020","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.msard.2022.103995_bib0012","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/1352458520917925","article-title":"Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri(\u00ae) Observational Program (TOP)","volume":"27","author":"Butzkueven","year":"2021","journal-title":"Mult. Scler."},{"issue":"14","key":"10.1016\/j.msard.2022.103995_bib0013","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1212\/01.wnl.0000277457.17420.b5","article-title":"The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL","volume":"69","author":"Calabresi","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.103995_bib0014","series-title":"Four-year longitudinal index stability data from the STRATIFY-2 study","author":"Campagnolo","year":"2016"},{"key":"10.1016\/j.msard.2022.103995_bib0015","unstructured":"Carillo-Infante, C., Richman, S., Yu, B., 2016. Functional and survival outcomes of asymptomatic progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients. ECTRIMS, London, UK, September 14-17 P1528."},{"issue":"3","key":"10.1016\/j.msard.2022.103995_bib0016","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/jcph.1737","article-title":"Modeling the efficacy of natalizumab in multiple sclerosis patients who switch from every-4-week dosing to extended-interval dosing","volume":"61","author":"Chang","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.msard.2022.103995_bib0017","article-title":"PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study","author":"Chisari","year":"2021","journal-title":"J. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2022.103995_bib0018","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/jnnp-2020-323472","article-title":"Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis","volume":"91","author":"Chisari","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2022.103995_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102439","article-title":"Effects of MS disease-modifying therapies on responses to vaccinations: a review","volume":"45","author":"Ciotti","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.103995_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102974","article-title":"Natalizumab discontinuation in a Dutch real-world cohort","volume":"52","author":"Coerver","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10","key":"10.1016\/j.msard.2022.103995_bib0021","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1177\/1352458520969145","article-title":"BEST-MS: a prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS","volume":"27","author":"Cohen","year":"2021","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2022.103995_bib0022","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41582-020-00427-y","article-title":"Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease","volume":"17","author":"Cortese","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2022.103995_bib0023","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.msard.2019.05.026","article-title":"The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study","volume":"33","author":"Curti","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.103995_bib0024","article-title":"Real-world data regarding long-term administration of natalizumab from a neurology department along literature review","author":"Davidescu","year":"2021","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.msard.2022.103995_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117385","article-title":"MRI activity and extended interval of natalizumab dosing regimen: a multicentre Italian study","volume":"424","author":"De Mercanti","year":"2021","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.msard.2022.103995_bib0026","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1177\/1352458520912637","article-title":"Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis","volume":"27","author":"Demortiere","year":"2021","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2022.103995_bib0027","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/1352458514546790","article-title":"Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study","volume":"21","author":"Ebrahimi","year":"2015","journal-title":"Mult. Scler."},{"issue":"10","key":"10.1016\/j.msard.2022.103995_bib0028","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s40261-021-01073-y","article-title":"Long-term effectiveness of natalizumab in patients with relapsing-remitting multiple sclerosis treated in the routine care in greece: results from the multicenter, observational 5-year prospective study 'TOPICS Greece'","volume":"41","author":"Efthimios","year":"2021","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.msard.2022.103995_bib0029","article-title":"The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis","volume":"39","author":"Foley","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.103995_bib0030","series-title":"ECTRIMS. October 13-15. Virtual. P970","article-title":"Primary results of NOVA: a randomised controlled study of the efficacy of 6-week dosing of natalizumab versus continued 4-week treatment for multiple sclerosis","author":"Foley","year":"2021"},{"issue":"4","key":"10.1016\/j.msard.2022.103995_bib0031","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1017\/cjn.2020.66","article-title":"Treatment optimization in multiple sclerosis: Canadian MS working group recommendations","volume":"47","author":"Freedman","year":"2020","journal-title":"Can. J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.msard.2022.103995_bib0032","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12883-016-0674-4","article-title":"Evaluation of pregnancy outcomes from the Tysabri\u00ae (natalizumab) pregnancy exposure registry: a global, observational, follow-up study","volume":"16","author":"Friend","year":"2016","journal-title":"BMC Neurol."},{"issue":"11","key":"10.1016\/j.msard.2022.103995_bib0033","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1007\/s10072-021-05127-z","article-title":"Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years","volume":"42","author":"Guerra","year":"2021","journal-title":"Neurol Sci."},{"issue":"11","key":"10.1016\/j.msard.2022.103995_bib0034","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.1007\/s00415-021-10559-w","article-title":"Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS treatment registry","volume":"268","author":"Guger","year":"2021","journal-title":"J. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2022.103995_bib0035","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1007\/s00415-019-09464-0","article-title":"Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS treatment registry","volume":"266","author":"Guger","year":"2019","journal-title":"J. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2022.103995_bib0036","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamaneurol.2014.209","article-title":"Natalizumab use during the third trimester of pregnancy","volume":"71","author":"Haghikia","year":"2014","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/j.msard.2022.103995_bib0037","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1212\/CPJ.0000000000000809","article-title":"Effect of switching from natalizumab to moderate- vs high-efficacy DMT in clinical practice","volume":"10","author":"Hersh","year":"2020","journal-title":"Neurol. Clin. Pract."},{"issue":"11","key":"10.1016\/j.msard.2022.103995_bib0038","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2022.103995_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102543","article-title":"Long-term effectiveness of natalizumab on MRI outcomes and no evidence of disease activity in relapsing-remitting multiple sclerosis patients treated in a Czech Republic real-world setting: a longitudinal, retrospective study","volume":"46","author":"Horakova","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2022.103995_bib0040","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.nrl.2010.10.004","article-title":"Natalizumab for relapsing-remitting multiple sclerosis","volume":"26","author":"Horga","year":"2011","journal-title":"Neurologia"},{"issue":"3","key":"10.1016\/j.msard.2022.103995_bib0041","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00415-009-0093-1","article-title":"The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL","volume":"256","author":"Hutchinson","year":"2009","journal-title":"J. Neurol."},{"issue":"1074","key":"10.1016\/j.msard.2022.103995_bib0042","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20160721","article-title":"Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications","volume":"90","author":"Igra","year":"2017","journal-title":"Br. J. Radiol."},{"issue":"3","key":"10.1016\/j.msard.2022.103995_bib0043","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/ana.24339","article-title":"Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis","volume":"77","author":"Kalincik","year":"2015","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2022.103995_bib0044","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","article-title":"Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension","volume":"17","author":"Kapoor","year":"2018","journal-title":"Lancet Neurol."},{"issue":"8","key":"10.1016\/j.msard.2022.103995_bib0045","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1474-4422(11)70149-1","article-title":"Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring","volume":"10","author":"Kappos","year":"2011","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.msard.2022.103995_bib0046","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1007\/s00415-012-6809-7","article-title":"Clinical effects of natalizumab on multiple sclerosis appear early in treatment course","volume":"260","author":"Kappos","year":"2013","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2022.103995_bib0047","article-title":"Patient and treatment characteristics and safety outcomes of patients with relapsing-remitting multiple sclerosis treated with natalizumab in Greece: results from the multicenter, 5-year prospective observational study 'TOPICS Greece'","volume":"7","author":"Karanasios","year":"2021","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2022.103995_bib0048","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.549842","article-title":"Natalizumab in multiple sclerosis treatment: from biological effects to immune monitoring","volume":"11","author":"Khoy","year":"2020","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.msard.2022.103995_bib0049","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/1352458516643393","article-title":"A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod","volume":"23","author":"Koch-Henriksen","year":"2017","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2022.103995_bib0050","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1017\/S0317167100011811","article-title":"The Toronto observational study of natalizumab in multiple sclerosis","volume":"38","author":"Krysko","year":"2011","journal-title":"Can. J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.msard.2022.103995_bib0051","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2018.12.022","article-title":"Inflammatory bowel disease in pregnancy clinical care pathway: a report from the american gastroenterological association IBD parenthood project working group","volume":"156","author":"Mahadevan","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.msard.2022.103995_bib0052","series-title":"Low risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients who were anti-JC virus antibody negative at baseline","author":"Mason","year":"2019"},{"issue":"2","key":"10.1016\/j.msard.2022.103995_bib0053","first-page":"117","article-title":"Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group","volume":"87","author":"McGuigan","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.msard.2022.103995_bib0054","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJMoa020696","article-title":"A controlled trial of natalizumab for relapsing multiple sclerosis","volume":"348","author":"Miller","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2022.103995_bib0055","series-title":"COVID-19 vaccine guidance for people living with MS","year":"2021"},{"issue":"2","key":"10.1016\/j.msard.2022.103995_bib0056","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/2040622313514790","article-title":"First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks","volume":"5","author":"Nicholas","year":"2014","journal-title":"Ther. Adv. Chronic Dis."},{"issue":"1","key":"10.1016\/j.msard.2022.103995_bib0057","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1212\/WNL.0000000000000541","article-title":"Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study","volume":"83","author":"O'Connor","year":"2014","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2022.103995_bib0058","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1017\/cjn.2015.296","article-title":"Use of natalizumab in patients with multiple sclerosis: 2015 update","volume":"42","author":"O'Connor","year":"2015","journal-title":"Can. J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.msard.2022.103995_bib0059a","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/ene.13537","article-title":"Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy","volume":"25","author":"Olberg","year":"2018","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.msard.2022.103995_bib0059","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/ene.12204","article-title":"A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort","volume":"21","author":"Outteryck","year":"2014","journal-title":"Eur. J. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2022.103995_bib0060","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1212\/NXI.0000000000000297","article-title":"Risk of relapse after natalizumab withdrawal: results from the French TYSEDMUS cohort","volume":"3","author":"Papeix","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"9","key":"10.1016\/j.msard.2022.103995_bib0061","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.msard.2022.103995_bib0062","first-page":"e823","article-title":"Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: fetal risks","volume":"90","author":"Portaccio","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.103995_bib0063","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.715195","article-title":"Drug and neurofilament levels in serum and breastmilk of women with multiple sclerosis exposed to natalizumab during pregnancy and lactation","volume":"12","author":"Proschmann","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.msard.2022.103995_bib0064","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/1352458511417481","article-title":"Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis","volume":"18","author":"Prosperini","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.103995_bib0065","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419837809","article-title":"Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis","volume":"12","author":"Prosperini","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"2","key":"10.1016\/j.msard.2022.103995_bib0066","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s00415-016-8343-5","article-title":"Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-na\u00efve patients with multiple sclerosis","volume":"264","author":"Prosperini","year":"2017","journal-title":"J. Neurol."},{"issue":"1-2","key":"10.1016\/j.msard.2022.103995_bib0067","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00508-019-1448-y","article-title":"Immunosuppressives and biologics during pregnancy and lactation: a consensus report issued by the Austrian societies of gastroenterology and hepatology and rheumatology and rehabilitation","volume":"131","author":"Puchner","year":"2019","journal-title":"Wien. Klin. Wochenschr."},{"issue":"17","key":"10.1016\/j.msard.2022.103995_bib0068","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.103995_bib0069","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.614715","article-title":"Does extended interval dosing natalizumab preserve effectiveness in multiple sclerosis? A 7 year-retrospective observational study","volume":"12","author":"Riancho","year":"2021","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.msard.2022.103995_bib0070","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.msard.2022.103995_bib0071","doi-asserted-by":"crossref","first-page":"e1452","DOI":"10.1212\/WNL.0000000000008243","article-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing","volume":"93","author":"Ryerson","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2022.103995_bib0072","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.autrev.2018.09.012","article-title":"A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis","volume":"18","author":"Sellner","year":"2019","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/j.msard.2022.103995_bib0073","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1212\/CPJ.0000000000000227","article-title":"Comparative efficacy of first-line natalizumab vs IFN-\u03b2 or glatiramer acetate in relapsing MS","volume":"6","author":"Spelman","year":"2016","journal-title":"Neurol. Clin. Pract."},{"issue":"4","key":"10.1016\/j.msard.2022.103995_bib0074","first-page":"e14764","article-title":"Risk of progressive multifocal leukoencephalopathy in multiple sclerosis patient treated with natalizumab: a systematic review","volume":"13","author":"Vivekanandan","year":"2021","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.msard.2022.103995_bib0075","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamaneurol.2019.2670","article-title":"Progressive multifocal leukoencephalopathy incidence and risk stratification among natalizumab users in france","volume":"77","author":"Vukusic","year":"2020","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.msard.2022.103995_bib0076","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/1352458520926869","article-title":"Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program","volume":"27","author":"Wiendl","year":"2021","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2022.103995_bib0077","first-page":"26","article-title":"Moving Towards a Cure for MS: Increased Immunosuppression and Striving for no evidence of disease activity (NEDA)","volume":"101","author":"Wong","year":"2018","journal-title":"R. I. Med. J."},{"key":"10.1016\/j.msard.2022.103995_bib0078","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103225","article-title":"MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis","volume":"56","author":"Yamout","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"24","key":"10.1016\/j.msard.2022.103995_bib0079","doi-asserted-by":"crossref","first-page":"e2989","DOI":"10.1212\/WNL.0000000000012084","article-title":"Natalizumab, fingolimod and dimethyl fumarate use and pregnancy-related relapse and disability in women with multiple sclerosis","volume":"96","author":"Yeh","year":"2021","journal-title":"Neurology"},{"issue":"15","key":"10.1016\/j.msard.2022.103995_bib0080","first-page":"e1452","article-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing","volume":"93","author":"Zhovtis Ryerson","year":"2019","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822005065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822005065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:03:46Z","timestamp":1761901426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822005065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":81,"alternative-id":["S2211034822005065"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.103995","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of natalizumab in persons with multiple sclerosis: 2022 update","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.103995","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103995"}}